Preparation, physiochemical characterization, and oral immunogenicity of Aβ(1-12), Aβ(29-40), and Aβ(1-42) loaded PLG microparticles formulations

Journal of Pharmaceutical Sciences

Volumn 98, Issue 6, 2009, Pages 2027-2039

  Rajkannan, R ^a,b   Arul, V ^a   Padma Malar, E J ^b   Jayakumar, R ^a  

^a CENTRAL LEATHER RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF MADRAS   (India)

Author keywords

Anti A antibodies; A PLG microparticles oral vaccine; B cell epitope A (1 12); Biodegradable polymers; Microparticles; Mucosal immunization; Oral AD vaccine; Peptide delivery; T cell epitope A (29 40); Vaccine adjuvants

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-12]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[29-40]; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; POLYGLACTIN; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BINDING; DRUG DEGRADATION; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; EMULSION; EVAPORATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN;

EID: 67049096369     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21600     Document Type: Article

References (41)

1. Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ. 2002. A liposome-base therapeutic vaccine against beta-amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci 9:2332-2337. (Pubitemid 34169061)
2. Spooner ET, Desai RV, Mori C, Leverone JF, Lemere CA. 2002. The generation and characterization of potentially therapeutic Abeta antibodies in mice: Differences according to strain and immunization protocol. Vaccine 21:290-297. (Pubitemid 35346823)
3. Pan W, Solomon B, Maness LM, Kastin AJ. 2002. Antibodies to beta-amyloid decrease the blood-tobrain transfer of beta-amyloid peptide. Exp Biol Med 227:609-615.
4. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. 2004. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci 101:14657-14662. (Pubitemid 39346739)
5. 5a. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. 2000. Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
6. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. 2000. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985. (Pubitemid 32101645)
7. Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA. 2003. Abeta 1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Vaccine 21:2197-2206.
8. Selkoe DJ, Schenk D. 2003. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584. (Pubitemid 37372653)
9. Chauhan NB, Siegel GJ. 2005. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci Lett 375:143-147. (Pubitemid 40202940)
10. Manea M, Mezo G, Hudecz F, Przybylski M. 2004. Polypeptide conjugates comprising a beta-amyloid plaque-specific epitope as new vaccine structures against Alzheimer's disease. Biopolymers 76:503-511. (Pubitemid 40007183)
11. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. 2003. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112:415-422. (Pubitemid 38063770)
12. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P. 2002. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269. (Pubitemid 35373558)
13. Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. 2001. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19:1940-1950. (Pubitemid 32178342)
14. Budhian A, Siegel SJ, Winey KI. 2008. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 346:151-159. (Pubitemid 350101995)
15. Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Guidice GD, O'Hagan DT. 2006. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 4:1680-1686. (Pubitemid 43238245)
16. Evans JT, Ward JR, Kern J, Johnson ME. 2004. A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine 22:1964-1972. (Pubitemid 38581066)
17. Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. 2005. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 73:828-833. (Pubitemid 40165739)
18. Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O'hagan DT. 2006. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 110:566-573.
19. Jiao Y, Ubrich N, Hoffart V, Marchand-Arvier M, Vigneron C, Hoffman M, Maincent P. 2002. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J Pharm Sci 91:760-768. (Pubitemid 34639639)
20. Yeh MK, Liu YT, Chen JL, Chiang CH. 2002. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J Control Release 82:237-247. (Pubitemid 34880181)
21. Smyth SH, Feldhaus S, Schumacher U, Carr KE. 2008. Uptake of inert microparticles in normal and immune deficient mice. Int J Pharm 346:109-118. (Pubitemid 350101999)
22. Freitas S, Merkle HP, Gander B. 2005. Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology. J Control Release 102:313-332. (Pubitemid 40093756)
23. Singh M, O'Hagan DT. 2002. Recent advances in vaccine adjuvants. Pharm Res 19:715-728. (Pubitemid 34686729)
24. Zhang XQ, Dahle CE, Weiner GJ, Salem AK. 2007. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci 96:3283-3292.
25. Fields GB, Noble RL. 1990. Solid phase peptide synthesis utilizing 9fluoroenylmethoxy carbonyl amino acids. Int J Pept Protein Res 35:161-214. (Pubitemid 20126875)
26. Chan WC, White PD. 2000. Fmoc solid phase peptide synthesis: A practical approach. New York: Oxford University Press Inc.
27. Rajkannan R, Dhanaraju MD, Gopinath D, Selvaraj D, Jayakumar R. 2006. Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles. Vaccine 24:5149-5157. (Pubitemid 43818197)
28. Dhanaraju MD, Rajkannan R, Selvaraj D, Jayakumar R, Vamsadhara C. 2006. Biodegradation and biocompatibility of contraceptive-steroid-loaded poly (DL-lactide-co-glycolide) injectable microspheres: In vitro and in vivo study. Contraception 74:148-156. (Pubitemid 44062465)
29. Delgado A, Lavelle EC, Hartshorne M, Davis SS. 1999. PLG microparticles stabilized using enteric coating polymers as oral vaccine delivery systems. Vaccine 17:2927-2938. (Pubitemid 29323021)
30. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O'Hagan DT. 1992. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76:164-168.
31. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, Paranjape R, Kulkarni S, Rao DN. 2005. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 23:5599-5617. (Pubitemid 41608610)
32. O'Hagan DT, Singh M, Ulmer JB. 2006. Microparticle-based technologies for vaccines. Methods 40:10-19. (Pubitemid 44415494)
33. De Magistris MT. 2006. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 58:52-67.
34. Yang YY, Chung TS, Ng NP. 2001. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22:231-241.
35. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. 2005. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57:391-410. (Pubitemid 39550967)
36. Yeh MK, Chiang CH. 2004. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: In vitro release and oral vaccination. J Microencapsul 21:91-106.
37. He X, Jiang L, Wang F, Xiao Z, Li J, Liu LS, Li D, Ren D, Jin X, Li K, He Y, Shi K, Guo Y, Zhang Y, Sun S. 2005. Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. J Control Release 107:357-372. (Pubitemid 41316297)
38. Allison SD. 2008. Effect of structural relaxation on the preparation and drug release behavior of poly (lactic-co-glycolic)acid microparticle drug delivery systems. J Pharm Sci 97:2022-2035.
39. Cleland JL, Barrón L, Berman PW, Daugherty A, Gregory T, Lim A, Vennari J, Wrin T, Powell MF. 1996. Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. J Pharm Sci 85:1346-1349. (Pubitemid 27014192)
40. Wang F, He XW, Jiang L, Ren D, He Y, Li DA, Sun SH. 2006. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 24:2017-2026. (Pubitemid 43255142)
41. Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. 2007. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int J Pharm 331:228-232. (Pubitemid 46223618)